GitHub is adopting AI-based scanning for its Code Security tool to expand vulnerability detections beyond the CodeQL static analysis and cover more languages and frameworks. The developer ...

Alice Chawner has had five surgeries since an MRI scan revealed she had a brain tumor after the fall Lexi Lane is a weekend banking writer at PEOPLE. She first joined as a member of the PEOPLE App ...

FORM OF A VERY SPECIAL APP. IF I TOUCH THIS AND THIS, I DON’T FEEL ANYTHING ON THIS SIDE AT ALL. SO THERE’S NO SENSATION. SANDHYA JEJURIKAR HAS NO FEELING ON THE LEFT SIDE OF HER FACE AND NO HEARING ...

Mark Kashef examines how integrating Obsidian, a markdown-based note-taking application, with Claude Code, an AI-driven automation system, can streamline information management. Obsidian’s graph ...

Researchers say they’ve discovered a supply-chain attack flooding repositories with malicious packages that contain invisible code, a technique that’s flummoxing traditional defenses designed to ...

Computer engineers and programmers have long relied on reverse engineering as a way to copy the functionality of a computer program without copying that program’s copyright-protected code directly.

The term “brain tumor” carries a particularly scary connotation. And if you’re a fan of TV medical dramas, you may think they’re quite common. However, less than 1% of Americans are living with a ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease. By Rebecca Robbins and Gina Kolata A ...

Free AI tools Goose and Qwen3-coder may replace a pricey Claude Code plan. Setup is straightforward but requires a powerful local machine. Early tests show promise, though issues remain with accuracy ...

Goose acts as the agent that plans, iterates, and applies changes. Ollama is the local runtime that hosts the model. Qwen3-coder is the coding-focused LLM that generates results. If you've been ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including a candidate that is less than two weeks away from an approval decision.